Bortezomib-based therapy is effective and well tolerated in frontline and multiply pre-treated Waldenstrom macroglobulinaemia including BTKi failures: A real-world analysis.

ABSTRACT: Waldenström macroglobulinemia (WM) is a rare, incurable low grade lymphoma following a relapsing trajectory. Management strategies have evolved with the introduction of targeted therapy including new classes of Bruton tyrosine kinase inhibitor (BTKi). Treatment may however be limited particularly at relapse by a lack of drug availability and tolerability. We assessed the real-world efficacy and tolerability of bortezomib-containing regimens in patients with WM at frontline and relapse including those with prior BTKi resistance. Forty-one patients were identified with 44 bortezomib-containing regimens administered (n = 12 frontline, n = 32 relapse). Of patients treated at relapse, the median prior lines of therapy was 3 (range 1-7). 24% (10/41) of the cohort were refractory or

SUBMITTER: Khwaja J 

PROVIDER: S-EPMC9713031 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature